ATARA Biotherapeutics (ATRA) Tops Q3 EPS by 4c

ATARA Biotherapeutics (NASDAQ: ATRA) reported Q3 EPS of ($0.90), $0.04 better than the analyst estimate of ($0.94). Revenue for the quarter came in at $5.4 million versus the consensus estimate of $3.92 million.

For earnings history and earnings-related data on ATARA Biotherapeutics (ATRA) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Green Dot and CommerceOne shareholders approve acquisition deal